AbbVie announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ® in atopic dermatitis and new data on SKYRIZI® in psoriasis and psoriatic arthritis, at the 30th European Academy of Dermatology and Venereology (EADV) Congress, to be held virtually on September 29-October 2.